Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study

Marc Scherlinger; Claire Carcaud; Marie-Elise Truchetet; Thomas Barnetche; Pierre Duffau; Lionel Couzi; Julien Seneschal; Patrick Blanco; Estibaliz Lazaro; Christophe Richez

doi:10.1136/annrheumdis-2018-214833

Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study

Ann Rheum Dis. 2019 Jul;78(7):1007-1010. doi: 10.1136/annrheumdis-2018-214833. Epub 2019 Jan 4.

Authors

Marc Scherlinger^#^{1

2

3}, Claire Carcaud^#^{1

2}, Marie-Elise Truchetet^{1

2

3}, Thomas Barnetche¹, Pierre Duffau^{1

2

3}, Lionel Couzi^{1

2

3}, Julien Seneschal^{1

2}, Patrick Blanco^{1

2

3}, Estibaliz Lazaro^#^{4

2

3}, Christophe Richez^#^{4

2

3}

Affiliations

¹ Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, Bordeaux, France.
² Université de Bordeaux, Bordeaux, France.
³ CNRS-UMR 5164 Immuno ConcEpT, Bordeaux, France.
⁴ Centre Hospitalier Universitaire de Bordeaux, FHU ACRONIM, Bordeaux, France estibaliz.lazaro@chu-bordeaux.fr christophe.richez@chu-bordeaux.fr.

^# Contributed equally.

PMID: 30610064
DOI: 10.1136/annrheumdis-2018-214833

No abstract available

Keywords: B-cells; clinical trial; rituximab; systemic lupus erythematosus; treatment.

Publication types

Letter

MeSH terms

Adult
Antirheumatic Agents / therapeutic use*
Female
Humans
Lupus Erythematosus, Systemic / drug therapy*
Lupus Erythematosus, Systemic / pathology
Male
Middle Aged
Randomized Controlled Trials as Topic
Rituximab / therapeutic use*
Severity of Illness Index*
Treatment Failure

Substances

Antirheumatic Agents
Rituximab